The Rebound Effect on Repeated Low-Level Red Light Therapy for Myopia
NCT: NCT07748546 · NOT_YET_RECRUITING
Brief Summary
Myopia is a global public health issue, projected to affect 49.8% of the world population by 2050, increasing risks of cataracts, glaucoma, macular degeneration, and retinal detachment. Repeated low-level red light (RLRL) therapy has shown promising myopia control in 12-month trials, reducing axial elongation by 69.4% and refractive progression by 76.6% versus spectacles, outperforming 0.01% atropine and benefiting orthokeratology poor responders. However, two-year data indicate declining efficacy in the second year and a rebound effect upon discontinuation, with progression rates matching untreated controls. This study enrolls participants who completed one year of continuous RLRL therapy to evaluate rebound effects on axial length and spherical equivalent refractive power among those who discontinue, gradually reduce, or continue treatment. Findings will inform strategies to optimize long-term RLRL protocols and mitigate post-treatment rebound.
Frequently Asked Questions
What is The Rebound Effect on Repeated Low-Level Red Light Therapy for Myopia?
The Rebound Effect on Repeated Low-Level Red Light Therapy for Myopia is a clinical trial registered under NCT07748546. Current status: NOT_YET_RECRUITING.
What is the status of NCT07748546?
The current status of NCT07748546 (The Rebound Effect on Repeated Low-Level Red Light Therapy for Myopia) is: NOT_YET_RECRUITING.
When did The Rebound Effect on Repeated Low-Level Red Light Therapy for Myopia start?
The Rebound Effect on Repeated Low-Level Red Light Therapy for Myopia started on 2026-08-15.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.